Replimune Group Inc (REPL) — Top EPS Revision Performer
As of 2026-05-05, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 46.40%. Featured in 1 EPS revision report, most recently on 2026-04-22. Sector: Healthcare.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 46.40%
- EPS growth this year
- 0.77%
- EPS next quarter (est)
- $-0.65
- Last price
- $2.87
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-05 | 46.40% | 0.77% | $-0.65 | $2.87 |
| 2026-05-04 | 46.40% | 0.77% | $-0.65 | $3.03 |
| 2026-05-03 | 46.40% | 0.77% | $-0.65 | $2.50 |
| 2026-04-30 | 46.40% | 0.77% | $-0.65 | $2.57 |
| 2026-04-29 | 46.40% | 0.77% | $-0.65 | $2.38 |
| 2026-04-28 | 46.40% | 0.77% | $-0.65 | $2.57 |
| 2026-04-27 | 46.40% | 0.77% | $-0.65 | $2.68 |
| 2026-04-26 | 46.40% | 0.77% | $-0.65 | $2.42 |
| 2026-04-24 | 46.40% | 0.77% | $-0.65 | $2.42 |
| 2026-04-23 | 46.40% | 0.77% | $-0.65 | $2.85 |
| 2026-04-22 | 46.40% | 0.77% | $-0.65 | $2.27 |
| 2026-04-21 | 46.40% | 0.77% | $-0.65 | $1.86 |
| 2026-04-20 | 46.40% | 0.77% | $-0.65 | $2.07 |
| 2026-04-19 | 46.40% | 0.77% | $-0.65 | $2.17 |
| 2026-04-16 | 46.40% | 0.77% | $-0.65 | $2.19 |
| 2026-04-15 | 46.40% | 0.77% | $-0.65 | $2.28 |
| 2026-04-14 | 46.40% | 0.77% | $-0.65 | $1.95 |
| 2026-04-13 | 46.40% | 0.77% | $-0.65 | $1.70 |
| 2026-04-12 | 34.42% | -1.33% | $-0.69 | $4.76 |
| 2026-04-10 | 32.20% | -1.61% | $-0.71 | $4.76 |
| 2026-04-09 | 32.20% | -1.61% | $-0.71 | $5.91 |
| 2026-04-08 | 32.20% | N/A | $-0.71 | $5.89 |
| 2026-04-07 | 32.20% | N/A | $-0.71 | $7.80 |
| 2026-04-06 | 32.20% | N/A | $-0.71 | $7.80 |
| 2026-04-05 | 32.20% | N/A | $-0.71 | $8.41 |
| 2026-04-03 | 32.20% | N/A | $-0.71 | $7.80 |
| 2026-04-02 | 32.20% | N/A | $-0.71 | $7.80 |
| 2026-04-01 | 32.20% | N/A | $-0.71 | $7.80 |
| 2026-04-01 | 32.20% | N/A | N/A | $7.65 |
| 2026-04-01 | 32.20% | N/A | N/A | $7.61 |
Reports Featuring REPL
Recent News
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.Barrons.com
- Replimune melanoma therapy rejected by FDA, shares plungeProactive
- FDA issues complete response letter to Replimunes RP1 for melanomaPharmaceutical Technology
- Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgradedInvesting.com
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
EPS revision data sourced from analyst consensus estimates, refreshed daily. Replimune Group Inc (REPL) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports